Stem cell therapy Market By Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells, Other), By Application (Cancer, Musculoskeletal Disorder, Wounds and Injuries, Cardiovascular Disease, Other), By Type (Allogeneic Transplants, Autologous Transplants): Global Opportunity Analysis and Industry Forecast, 2021-2031

Stem cell therapy Market

Stem cell therapy is a type of regenerative medicine developed to repair damaged cells within the body by reducing inflammation and modulating the immune system. This phenomenon makes stem cell therapy a viable treatment option for a variety of medical conditions. Stem cells have tremendous promise to help understand and treat a range of diseases, injuries and other health-related conditions. Their potential is evident in the use of blood stem cells to treat diseases of the blood, a therapy that has saved the lives of thousands of children with leukemia; and can be seen in the use of stem cells for tissue grafts to treat diseases or injury to the bone, skin and surface of the eye. However, the important clinical trials involving stem cells are underway for many other conditions and researchers continue to explore new avenues using stem cells in medicine. The key drivers of the global stem cell therapy market are increase in demand for stem cell therapy, increase in government support for research and development activities and increase in healthcare expenditure have significantly contributed toward the growth of the market. Promising drugs in late stage of pipeline with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, high cost of stem cell therapy impedes the market growth.

The COVID-19 pandemic affected the stem cell therapy industry in a negative way, like various other cell and gene therapies industries were affected. According to the data of National Institute of Health, the coronavirus (COVID-19) has caused significant disruption to the stem cell therapy industry, which has historically faced substantial complexities in supply of materials, and manufacturing and logistics processes. The costs and reimbursements associated with stem cell therapy increased in the pandemic owing to the lockdown laws imposed during pandemic.

By cell source, the market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells, other. The adipose tissue-derived mesenchymal stem cells segment was the major revenue contributor of stem cell therapy market size in 2021 and is anticipated to continue this trend during the forecast period, due to increase in number of patients suffering from cancer. In addition, increasing target population, exposure to harmful radiation and increasing governmental initiatives also contributed toward the growth of the market.

On the other side, bone marrow-derived mesenchymal stem cells are projected to exhibit the fastest market growth during the forecast period, owing to higher incidence of the chronic and fatal diseases like musculoskeletal diseases, and rise in smoking of tobacco that includes passive smoking, which may lead to cancer.

By application, the market is classified into cancer, musculoskeletal disorders, wounds and injuries, cardiovascular diseases, gastrointestinal diseases, other. The cancer segment was the major revenue contributor of stem cell therapy market size in 2021 and is anticipated to continue this trend during the forecast period, due to increase in number of patients suffering from cardiovascular, musculoskeletal diseases. In addition, increasing research and development activities also contributed toward the growth of the market. On the other side, cancer is projected to exhibit the fastest market growth during the forecast period, owing to increase in the prevalence of the disease, and rise in number of accidents.

By type, the market is classified into allogeneic transplants and autologous transplants. Furthermore, the allogeneic transplants segment is sub-classified as pediatric and adult. Also, the autologous transplants segment is sub-classified as pediatric and adult. The autologous transplants segment is anticipated to grow with the largest share throughout the forecast period. This is attributed to increase in use of autologous stem cells, and availability of number of stem cell products. Recent advances in cellular technology have contributed to improve the understanding of various disease cells and their metabolism at molecular level, thus driving the need for stem cell therapies for the treatment. On the other side, the demand for allogeneic transplants segment is projected to exhibit the fastest market growth during the forecast period due to its efficacy and expected launch of pipeline products.

By region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). North America accounted for the largest share of revenue in 2021, and is anticipated to maintain its dominance from 2021 to 2031, owing to presence of large patient population, strong presence of key players, ease of product availability, well developed healthcare infrastructure, favorable reimbursement policies in healthcare system, higher number of research, development, & innovation activities and higher adoption of advanced therapeutics. However, Asia-Pacific is expected to grow at the highest CAGR, owing to the stem cell therapy market trends like increase in number of cancer affected population and rise in number of applications of stem cell therapy.

KEY FINDINGS OF STUDY

By cell source, the bone marrow-derived mesenchymal stem cells segment is anticipated to grow with the highest CAGR throughout the forecast period.

By application, the cancer segment is anticipated to grow with the highest CAGR throughout the stem cell therapy market forecast period.

By type, the autologous transplants segment accounted for major stem cell therapy market share of the global stem cell therapy market in 2021.

Asia-Pacific is anticipated to grow at the highest rate during the stem cell therapy market analysis period.

Overview

The global stem cell therapy market was valued at $205.12 million in 2021, and is projected to reach $928.64 million by 2031, registering a CAGR of 16.2% from 2022 to 2031.

The stem cell therapy is a promising strategy for regeneration of damaged organs, tissues or functions through the transplantation of stem cells. The cell therapy involves the direct administration of cells into the body for healing purposes. The units of therapy in this approach are single cells. It has been established as a useful therapy for hematologic malignancies and some solid tumors. However, some of the patients still die in allogeneic stem cell transplantation because T-lymphocytes cause fatal GVHD, and many are not cured in autologous stem cell transplantation as the disease recurs post-stem cell transplantation. Hematopoietic stem cell therapies provide methods for inducing lifelong tolerance to xenografts or allow novel treatment of autoimmune diseases, whereas the research and use of nonhematopoietic stem cells help minimize the toxicities of cancer therapy or cure non-malignant disorders.

The global stem cell therapy market is anticipated to show significant market growth during the forecast period, owing to increase in demand for stem cell therapy, increase in government support for R&D activities and increase in healthcare expenditure. Furthermore, increase in prevalence of diseases such as cancer, and new product launches associated with stem cell therapy are considerably contributing toward the market growth. However, limitations on use of embryonic stem cells due to ethical concerns and high cost of stem cell therapy are negatively impacting the market growth. Conversely, surge in the applications of induced pluripotent stem cells in embryonic stem cell therapy offers the lucrative opportunities for the growth of the market.

The global stem cell therapy market is segmented on the basis of cell source, application, type and region. Based on cell source, the market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells, other. Based on application, the market is classified into cancer, musculoskeletal disorders, wounds and injuries, cardiovascular diseases, gastrointestinal diseases, other. Based on type, the market is classified into allogeneic transplants and autologous transplants. Furthermore, the allogeneic transplants segment is sub-classified as pediatric and adult. Also, the autologous transplants segment is sub-classified as pediatric and adult. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

The major companies profiled in the report include Allele Biotechnology and Pharmaceuticals, Inc., Astellas Pharma Inc, Fujifilm Holding Corporation (FUJIFILM Cellular Dynamics, Inc.), Mesoblast Ltd, Novadip Biosciences, NuVasive, Inc., Orthofix Holdings, Inc., Smith & Nephew plc, Takeda Pharmaceutical, and U.S. Stem Cell, Inc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stem cell therapy market analysis from 2021 to 2031 to identify the prevailing stem cell therapy market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the stem cell therapy market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global stem cell therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ U.S. Stem Cell, Inc

Scope of Stem cell therapy Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Adipose Tissue-Derived Mesenchymal Stem Cells

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Bone Marrow-Derived Mesenchymal Stem Cells

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Cord Blood/Embryonic Stem Cells

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Other

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Cancer

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Musculoskeletal Disorder

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Wounds and Injuries

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

5.5 Cardiovascular Disease

5.5.1 Key market trends, growth factors and opportunities

5.5.2 Market size and forecast, by region

5.5.3 Market analysis by country

5.6 Other

5.6.1 Key market trends, growth factors and opportunities

5.6.2 Market size and forecast, by region

5.6.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Allogeneic Transplants

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.2.4 Allogeneic Transplants Stem cell therapy Market by Age

6.2.4.1 Pediatric Market size and forecast, by region

6.2.4.2 Adult Market size and forecast, by region

6.3 Autologous Transplants

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.3.4 Autologous Transplants Stem cell therapy Market by Age

6.3.4.1 Pediatric Market size and forecast, by region

6.3.4.2 Adult Market size and forecast, by region

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Cell Source

7.2.3 North America Market size and forecast, by Application

7.2.4 North America Market size and forecast, by Type

7.2.4.1 North America Allogeneic Transplants Stem cell therapy Market by Age

7.2.4.2 North America Autologous Transplants Stem cell therapy Market by Age

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Market size and forecast, by Cell Source

7.2.5.1.2 Market size and forecast, by Application

7.2.5.1.3 Market size and forecast, by Type

7.2.5.2 Canada

7.2.5.2.1 Market size and forecast, by Cell Source

7.2.5.2.2 Market size and forecast, by Application

7.2.5.2.3 Market size and forecast, by Type

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Cell Source

7.3.3 Europe Market size and forecast, by Application

7.3.4 Europe Market size and forecast, by Type

7.3.4.1 Europe Allogeneic Transplants Stem cell therapy Market by Age

7.3.4.2 Europe Autologous Transplants Stem cell therapy Market by Age

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Market size and forecast, by Cell Source

7.3.5.1.2 Market size and forecast, by Application

7.3.5.1.3 Market size and forecast, by Type

7.3.5.2 France

7.3.5.2.1 Market size and forecast, by Cell Source

7.3.5.2.2 Market size and forecast, by Application

7.3.5.2.3 Market size and forecast, by Type

7.3.5.3 UK

7.3.5.3.1 Market size and forecast, by Cell Source

7.3.5.3.2 Market size and forecast, by Application

7.3.5.3.3 Market size and forecast, by Type

7.3.5.4 Rest of Europe

7.3.5.4.1 Market size and forecast, by Cell Source

7.3.5.4.2 Market size and forecast, by Application

7.3.5.4.3 Market size and forecast, by Type

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Cell Source

7.4.3 Asia-Pacific Market size and forecast, by Application

7.4.4 Asia-Pacific Market size and forecast, by Type

7.4.4.1 Asia-Pacific Allogeneic Transplants Stem cell therapy Market by Age

7.4.4.2 Asia-Pacific Autologous Transplants Stem cell therapy Market by Age

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Market size and forecast, by Cell Source

7.4.5.1.2 Market size and forecast, by Application

7.4.5.1.3 Market size and forecast, by Type

7.4.5.2 India

7.4.5.2.1 Market size and forecast, by Cell Source

7.4.5.2.2 Market size and forecast, by Application

7.4.5.2.3 Market size and forecast, by Type

7.4.5.3 South Korea

7.4.5.3.1 Market size and forecast, by Cell Source

7.4.5.3.2 Market size and forecast, by Application

7.4.5.3.3 Market size and forecast, by Type

7.4.5.4 Rest of Asia-Pacific

7.4.5.4.1 Market size and forecast, by Cell Source

7.4.5.4.2 Market size and forecast, by Application

7.4.5.4.3 Market size and forecast, by Type

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Cell Source

7.5.3 LAMEA Market size and forecast, by Application

7.5.4 LAMEA Market size and forecast, by Type

7.5.4.1 LAMEA Allogeneic Transplants Stem cell therapy Market by Age

7.5.4.2 LAMEA Autologous Transplants Stem cell therapy Market by Age

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Market size and forecast, by Cell Source

7.5.5.1.2 Market size and forecast, by Application

7.5.5.1.3 Market size and forecast, by Type

7.5.5.2 Rest of LAMEA

7.5.5.2.1 Market size and forecast, by Cell Source

7.5.5.2.2 Market size and forecast, by Application

7.5.5.2.3 Market size and forecast, by Type

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Allele Biotechnology and Pharmaceuticals, Inc.

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Astellas Pharma Inc.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Fujifilm Holding Corporation

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Mesoblast Ltd.

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Novadip Biosciences

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 NuVasive, Inc.

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Orthofix Holdings, Inc.

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Smith & Nephew plc

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Takeda Pharmaceutical Company Ltd

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 U.S. Stem Cell, Inc.

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 2. STEM CELL THERAPY MARKET, FOR ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS, BY REGION, 2021-2031 ($MILLION)

TABLE 3. STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 4. STEM CELL THERAPY MARKET, FOR BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, BY REGION, 2021-2031 ($MILLION)

TABLE 5. STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MESENCHYMAL STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 6. STEM CELL THERAPY MARKET, FOR CORD BLOOD/EMBRYONIC STEM CELLS, BY REGION, 2021-2031 ($MILLION)

TABLE 7. STEM CELL THERAPY MARKET FOR CORD BLOOD/EMBRYONIC STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 8. STEM CELL THERAPY MARKET, FOR OTHER, BY REGION, 2021-2031 ($MILLION)

TABLE 9. STEM CELL THERAPY MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 10. GLOBAL STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 11. STEM CELL THERAPY MARKET, FOR CANCER, BY REGION, 2021-2031 ($MILLION)

TABLE 12. STEM CELL THERAPY MARKET FOR CANCER, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 13. STEM CELL THERAPY MARKET, FOR MUSCULOSKELETAL DISORDER, BY REGION, 2021-2031 ($MILLION)

TABLE 14. STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDER, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 15. STEM CELL THERAPY MARKET, FOR WOUNDS AND INJURIES, BY REGION, 2021-2031 ($MILLION)

TABLE 16. STEM CELL THERAPY MARKET FOR WOUNDS AND INJURIES, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 17. STEM CELL THERAPY MARKET, FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2031 ($MILLION)

TABLE 18. STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 19. STEM CELL THERAPY MARKET, FOR OTHER, BY REGION, 2021-2031 ($MILLION)

TABLE 20. STEM CELL THERAPY MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 21. GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 22. STEM CELL THERAPY MARKET, FOR ALLOGENEIC TRANSPLANTS, BY REGION, 2021-2031 ($MILLION)

TABLE 23. STEM CELL THERAPY MARKET FOR ALLOGENEIC TRANSPLANTS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 24. GLOBAL ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 25. STEM CELL THERAPY MARKET, FOR PEDIATRIC, BY REGION, 2021-2031 ($MILLION)

TABLE 26. STEM CELL THERAPY MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)

TABLE 27. STEM CELL THERAPY MARKET, FOR AUTOLOGOUS TRANSPLANTS, BY REGION, 2021-2031 ($MILLION)

TABLE 28. STEM CELL THERAPY MARKET FOR AUTOLOGOUS TRANSPLANTS, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 29. GLOBAL AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 30. STEM CELL THERAPY MARKET, FOR PEDIATRIC, BY REGION, 2021-2031 ($MILLION)

TABLE 31. STEM CELL THERAPY MARKET, FOR ADULT, BY REGION, 2021-2031 ($MILLION)

TABLE 32. STEM CELL THERAPY MARKET, BY REGION, 2021-2031 ($MILLION)

TABLE 33. NORTH AMERICA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 34. NORTH AMERICA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 35. NORTH AMERICA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 36. NORTH AMERICA ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 37. NORTH AMERICA AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 38. NORTH AMERICA STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 39. U.S. STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 40. U.S. STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 41. U.S. STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 42. CANADA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 43. CANADA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 44. CANADA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 45. EUROPE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 46. EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 47. EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 48. EUROPE ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 49. EUROPE AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 50. EUROPE STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 51. GERMANY STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 52. GERMANY STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 53. GERMANY STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 54. FRANCE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 55. FRANCE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 56. FRANCE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 57. UK STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 58. UK STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 59. UK STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 60. REST OF EUROPE STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 61. REST OF EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 62. REST OF EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 63. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 64. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 65. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 66. ASIA-PACIFIC ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 67. ASIA-PACIFIC AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 68. ASIA-PACIFIC STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 69. JAPAN STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 70. JAPAN STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 71. JAPAN STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 72. INDIA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 73. INDIA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 74. INDIA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 75. SOUTH KOREA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 76. SOUTH KOREA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 77. SOUTH KOREA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 78. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 79. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 80. REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 81. LAMEA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 82. LAMEA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 83. LAMEA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 84. LAMEA ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 85. LAMEA AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET, BY AGE, 2021-2031 ($MILLION)

TABLE 86. LAMEA STEM CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)

TABLE 87. BRAZIL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 88. BRAZIL STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 89. BRAZIL STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 90. REST OF LAMEA STEM CELL THERAPY MARKET, BY CELL SOURCE, 2021-2031 ($MILLION)

TABLE 91. REST OF LAMEA STEM CELL THERAPY MARKET, BY APPLICATION, 2021-2031 ($MILLION)

TABLE 92. REST OF LAMEA STEM CELL THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)

TABLE 93.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

TABLE 94.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: OPERATING SEGMENTS

TABLE 95.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 96.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: NET SALES,

TABLE 97.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.: KEY STRATERGIES

TABLE 98.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT

TABLE 99.ASTELLAS PHARMA INC.: OPERATING SEGMENTS

TABLE 100.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO

TABLE 101.ASTELLAS PHARMA INC.: NET SALES,

TABLE 102.ASTELLAS PHARMA INC.: KEY STRATERGIES

TABLE 103.FUJIFILM HOLDING CORPORATION: COMPANY SNAPSHOT

TABLE 104.FUJIFILM HOLDING CORPORATION: OPERATING SEGMENTS

TABLE 105.FUJIFILM HOLDING CORPORATION: PRODUCT PORTFOLIO

TABLE 106.FUJIFILM HOLDING CORPORATION: NET SALES,

TABLE 107.FUJIFILM HOLDING CORPORATION: KEY STRATERGIES

TABLE 108.MESOBLAST LTD.: COMPANY SNAPSHOT

TABLE 109.MESOBLAST LTD.: OPERATING SEGMENTS

TABLE 110.MESOBLAST LTD.: PRODUCT PORTFOLIO

TABLE 111.MESOBLAST LTD.: NET SALES,

TABLE 112.MESOBLAST LTD.: KEY STRATERGIES

TABLE 113.NOVADIP BIOSCIENCES: COMPANY SNAPSHOT

TABLE 114.NOVADIP BIOSCIENCES: OPERATING SEGMENTS

TABLE 115.NOVADIP BIOSCIENCES: PRODUCT PORTFOLIO

TABLE 116.NOVADIP BIOSCIENCES: NET SALES,

TABLE 117.NOVADIP BIOSCIENCES: KEY STRATERGIES

TABLE 118.NUVASIVE, INC.: COMPANY SNAPSHOT

TABLE 119.NUVASIVE, INC.: OPERATING SEGMENTS

TABLE 120.NUVASIVE, INC.: PRODUCT PORTFOLIO

TABLE 121.NUVASIVE, INC.: NET SALES,

TABLE 122.NUVASIVE, INC.: KEY STRATERGIES

TABLE 123.ORTHOFIX HOLDINGS, INC.: COMPANY SNAPSHOT

TABLE 124.ORTHOFIX HOLDINGS, INC.: OPERATING SEGMENTS

TABLE 125.ORTHOFIX HOLDINGS, INC.: PRODUCT PORTFOLIO

TABLE 126.ORTHOFIX HOLDINGS, INC.: NET SALES,

TABLE 127.ORTHOFIX HOLDINGS, INC.: KEY STRATERGIES

TABLE 128.SMITH & NEPHEW PLC: COMPANY SNAPSHOT

TABLE 129.SMITH & NEPHEW PLC: OPERATING SEGMENTS

TABLE 130.SMITH & NEPHEW PLC: PRODUCT PORTFOLIO

TABLE 131.SMITH & NEPHEW PLC: NET SALES,

TABLE 132.SMITH & NEPHEW PLC: KEY STRATERGIES

TABLE 133.TAKEDA PHARMACEUTICAL COMPANY LTD: COMPANY SNAPSHOT

TABLE 134.TAKEDA PHARMACEUTICAL COMPANY LTD: OPERATING SEGMENTS

TABLE 135.TAKEDA PHARMACEUTICAL COMPANY LTD: PRODUCT PORTFOLIO

TABLE 136.TAKEDA PHARMACEUTICAL COMPANY LTD: NET SALES,

TABLE 137.TAKEDA PHARMACEUTICAL COMPANY LTD: KEY STRATERGIES

TABLE 138.U.S. STEM CELL, INC.: COMPANY SNAPSHOT

TABLE 139.U.S. STEM CELL, INC.: OPERATING SEGMENTS

TABLE 140.U.S. STEM CELL, INC.: PRODUCT PORTFOLIO

TABLE 141.U.S. STEM CELL, INC.: NET SALES,

TABLE 142.U.S. STEM CELL, INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.STEM CELL THERAPY MARKET SEGMENTATION

FIGURE 2.STEM CELL THERAPY MARKET,2021-2031

FIGURE 3.STEM CELL THERAPY MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.STEM CELL THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.STEM CELL THERAPY MARKET,BY CELL SOURCE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CORD BLOOD/EMBRYONIC STEM CELLS STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHER STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 17.STEM CELL THERAPY MARKET,BY APPLICATION,2021(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CANCER STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDER STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF WOUNDS AND INJURIES STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DISEASE STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF OTHER STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 23.STEM CELL THERAPY MARKET,BY TYPE,2021(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ALLOGENEIC TRANSPLANTS STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF AUTOLOGOUS TRANSPLANTS STEM CELL THERAPY MARKET,2021-2031(%)

FIGURE 26.STEM CELL THERAPY MARKET BY REGION,2021

FIGURE 27.U.S. STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 28.CANADA STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 29.GERMANY STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 30.FRANCE STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 31.UK STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 32.REST OF EUROPE STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 33.JAPAN STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 34.INDIA STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 35.SOUTH KOREA STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 36.REST OF ASIA-PACIFIC STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 37.BRAZIL STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 38.REST OF LAMEA STEM CELL THERAPY MARKET,2021-2031($MILLION)

FIGURE 39. TOP WINNING STRATEGIES, BY YEAR

FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 43.COMPETITIVE DASHBOARD

FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 45.ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC..: NET SALES ,($MILLION)

FIGURE 46.ASTELLAS PHARMA INC..: NET SALES ,($MILLION)

FIGURE 47.FUJIFILM HOLDING CORPORATION.: NET SALES ,($MILLION)

FIGURE 48.MESOBLAST LTD..: NET SALES ,($MILLION)

FIGURE 49.NOVADIP BIOSCIENCES.: NET SALES ,($MILLION)

FIGURE 50.NUVASIVE, INC..: NET SALES ,($MILLION)

FIGURE 51.ORTHOFIX HOLDINGS, INC..: NET SALES ,($MILLION)

FIGURE 52.SMITH & NEPHEW PLC.: NET SALES ,($MILLION)

FIGURE 53.TAKEDA PHARMACEUTICAL COMPANY LTD.: NET SALES ,($MILLION)

FIGURE 54.U.S. STEM CELL, INC..: NET SALES ,($MILLION